References
- Wang YC, McPherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet (London, England). 2011;378(9793):815–825.
- Terranova L, Busetto L, Vestri A, et al. Bariatric surgery: cost-effectiveness and budget impact. Obes Surg. 2012;22(4):646–653.
- Obesity and overweight. WHO (World Health Organization); 2016 [cited 2016 Jul 14]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/
- Simmonds M, Llewellyn A, Owen CG, et al. Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. Obes Rev. 2016;17(2):95–107.
- Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–38.
- Kolotkin RL, Meter K, Williams GR. Quality of life and obesity. Obes Rev. 2001;2(4):219–229.
- Simpson KA, Martin NM, Bloom SR. Hypothalamic regulation of appetite. Expert Rev Endocrinol Metab. 2008;3(5):577–592.
- Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature. 2006;444(7121):854–859.
- Ahima RS, Antwi DA. Brain regulation of appetite and satiety. Endocrinol Metab Clin North Am. 2008;37(4):811–823.
- Kim GW, Lin JE, Blomain ES, et al. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther. 2014;95(1):53–66.
- Jones BJ, Bloom SR. The new era of drug therapy for obesity: the evidence and the expectations. Drugs. 2015;75(9):935–945.
- Holst JJ. Incretin hormones and the satiation signal. Int J Obes (Lond). 2013 Sep;37(9):1161–1168.
- Troke RC, Tan TM, Bloom SR. The future role of gut hormones in the treatment of obesity. Ther Adv Chronic Dis. 2014;5(1):4–14.
- Münzberg H, Qualls-Creekmore E, Berthoud H-R, et al. Neural control of energy expenditure. Handb Exp Pharmacol. 2016;233:173–194.
- Leibel RL, Seeley RJ, Darsow T, et al. Biologic responses to weight loss and weight regain: report from an American Diabetes Association research symposium. Diabetes. 2015 Jul;64(7):2299–2309.
- Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes (Lond). 2010;34(Suppl 1(0 1)):S47–55.
- Rosenbaum M, Leibel RL. 20 years of leptin: role of leptin in energy homeostasis in humans. J Endocrinol. 2014;223(1):T83–96.
- MacLean PS, Higgins JA, Giles ED, et al. The role for adipose tissue in weight regain after weight loss. Obes Rev. 2015;16(Suppl 1):45–54.
- Reinhardt M, Thearle MS, Ibrahim M, et al. A human thrifty phenotype associated with less weight loss during caloric restriction. Diabetes. 2015;64(8):2859–2867.
- Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597–1604.
- Krentz AJ, Fujioka K, Hompesch M. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. Diabetes Obes Metab. 2016;18(6):558–570.
- Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf. 2012;11(3):459–471.
- Weintraub M, Sundaresan PR, Schuster B, et al. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Clin Pharmacol Ther. 1992;51(5):595–601.
- Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine–phentermine. N Engl J Med. 1997;337(9):581–588.
- Rodgers RJ, Tschöp MH, Wilding JPH. Anti-obesity drugs: past, present and future. Dis Model Mech. 2012;5(5):621–626.
- James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–917.
- Kirkham TC. Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiatry. 2009;21(2):163–171.
- Chorvat RJ. Peripherally restricted CB1 receptor blockers. Bioorg Med Chem Lett. 2013;23(17):4751–4760.
- Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013; 369(2):145–154.
- Kritchevsky SB, Beavers KM, Miller ME, et al. Intentional weight loss and all-cause mortality: a meta-analysis of randomized clinical trials. PLoS One. 2015;10(3):e0121993.
- Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014;22(1):5–13.
- Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events. JAMA. 2016;315(22):2424.
- Dalle Grave R, Calugi S, Molinari E, et al. Weight loss expectations in obese patients and treatment attrition: an observational multicenter study. Obes Res. 2005;13(11):1961–1969.
- Fildes A, Charlton J, Rudisill C, et al. Probability of an obese person attaining normal body weight: cohort study using electronic health records. Am J Public Health. 2015;105(9):e54–9.
- Sjöström L. Review of the key results from the Swedish obese subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–234.
- Wolfe BM, Kvach E, Eckel RH. Treatment of obesity. Circ Res. 2016;118(11):1844–1855.
- Tack J, Deloose E. Complications of bariatric surgery: dumping syndrome, reflux and vitamin deficiencies. Best Pract Res Clin Gastroenterol. 2014;28(4):741–749.
- Bray GA, Frühbeck G, Ryan DH, et al. Management of obesity. Lancet. 2016;387(10031):1947–1956.
- Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–424.
- Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161.
- Jacob S, Rabbia M, Meier MK, et al. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009;11(4):361–371.
- Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013 Jul;6(4):560–567.
- Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315(10):990–1004.
- Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–699.
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med: Published Online. 2016 Sep 15. DOI:10.1056/NEJMoa1607141.
- Dirksen C, Jørgensen NB, Bojsen-Møller KN, et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes (Lond). 2013;37(11):1452–1459.
- Le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007;246(5):780–785.
- De Hollanda A, Jiménez A, Corcelles R, et al. Gastrointestinal hormones and weight loss response after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2014;10(5):814–819.
- Tschöp MH, Finan B, Clemmensen C, et al. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab. 2016;24(1):51–62.
- Miras AD, Le Roux CW. Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery? Int J Obes (Lond). 2014;38(3):325–333.
- Sadry SA, Drucker DJ. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol. 2013;9(7):425–433.
- Araujo F, Shrestha N, Granja PL, et al. Antihyperglycemic potential of incretins orally delivered via nano and microsystems and subsequent glucoregulatory effects. Curr Pharm Biotechnol. 2014;15(7):609–619.
- Davies M, Pieber TR, Jabbour S, et al. Dose-dependent glucose lowering and body weight reductions with the novel oral formulation of semaglutide in patients with early type 2 diabetes. EASD Annu Meet 2016;Abstract 149 [cited 2016 Sep 19]. Available from: http://www.easdvirtualmeeting.org/resources/dose-dependent-glucose-lowering-and-body-weight-reductions-with-the-novel-oral-formulation-of-semaglutide-in-patients-with-early-type-2-diabetes
- Krishna R, Gumbiner B, Stevens C, et al. Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy. Clin Pharmacol Ther. 2009;86(6):659–666.
- Citeline’s Pharmaprojects, 2016.[cited 2016 Jun 15]. Available from: https://pipeline.citeline.com/CpLogin.aspx
- Orphan drug designations and approvals. U.S. Food and Drug Administration, 2016 [cited 2016 Aug 3]. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm
- Erondu N, Wadden T, Gantz I, et al. Effect of NPY5R antagonist MK-0557 on weight regain after very-low-calorie diet-induced weight loss. Obesity (Silver Spring). 2007;15(4):895–905.
- Omori N, Kouyama N, Yukimasa A, et al. Hit to lead SAR study on benzoxazole derivatives for an NPY Y5 antagonist. Bioorg Med Chem Lett. 2012;22(5):2020–2023.
- Poulton AS, Hibbert EJ, Champion BL, et al. Stimulants for the control of hedonic appetite. Front Pharmacol. 2016;7:105.
- Astrup A, Madsbad S, Breum L, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2008;372(9653):1906–1913.
- Gilbert J-A, Gasteyger C, Raben A, et al. The effect of tesofensine on appetite sensations. Obesity (Silver Spring). 2012;20(3):553–561.
- Astrup A, Madsbad S, Breum L, et al. Under-reporting of adverse effects of tesofensine. Lancet (London, England). 2013;382(9887):127.
- Frost A Wishful shrinking: is the pipeline for obesity therapies set to expand with waistlines? Citeline, 2015 [cited 2016 Aug 3]. Available from: https://citeline.com/wp-content/uploads/Citeline_Obesity_Whitepaper_V2_Final.pdf
- Kopelman P, Groot GDH, Rissanen A, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010 Jan;18(1):108–115.
- Boston therapeutics announces FDA acceptance of IND to initiate a clinical trial of BTI-320 to treat type ll diabetes and weight loss. Boston Therapeutics Inc. 2014 [cited 2016 Aug 3]. Available from: http://www.bostonti.com/news/press-releases/detail/814/boston-therapeutics-announces-fda-acceptance-of-ind-to
- Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36(8):2154–2161.
- Stenlöf K, Cefalu WT, Kim K-A, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–382.
- Erondu N, Hollander PA, Bays H, et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese adults. EASD Annu Meet 2016;Abstract 76 [cited 2016 Sep 15]. Available from: http://www.easdvirtualmeeting.org/resources/coadministration-of-canagliflozin-and-phentermine-for-weight-management-in-overweight-and-obese-adults
- Dangerous gamble with a new class of diabetes drugs. ISMP QuarterWatch Annual Report, 2016; [cited 2016 Aug 23] data from 2015 Q4. Available from: https://www.ismp.org/quarterwatch/pdfs/2015Q4.pdf
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
- Joharapurkar AA, Dhanesha NA, Jain MR. Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity. Diabetes Metab Syndr Obes. 2014;7:73–84.
- Zafgen announces beloranib IND placed on complete clinical hold. Zafgen Inc., 2015; [cited 2016 Aug 3]. Available from: http://ir.zafgen.com/releasedetail.cfm?ReleaseID=945314
- Beloranib demonstrates statistically and clinically significant improvements in body weight, body composition, and glycemic control in ZAF-203 clinical trial. Zafgen Inc., 2016; [cited 2016 Aug 3]. Available from: http://ir.zafgen.com/releasedetail.cfm?ReleaseID=975343
- Zafgen refocuses resources on development of differentiated second-generation MetAP2 inhibitor ZGN-1061. Zafgen Inc, 2016; [cited 2016 Aug 3]. Available from: http://ir.zafgen.com/releasedetail.cfm?ReleaseID=980192
- Jaoude J, Koh Y. Matrix metalloproteinases in exercise and obesity. Vasc Health Risk Manag. 2016;12:287–295.
- Okauchi Y, Nishizawa H, Funahashi T, et al. Reduction of visceral fat is associated with decrease in the number of metabolic risk factors in Japanese men. Diabetes Care. 2007;30(9):2392–2394.
- Pioneer in the Angiogenesis Biotech Industry. AngioLab Inc., 2016; [cited 2016 Aug 3]. Available from: http://www.angiolab.co.kr/html/product_02e.php
- Slentz CA, Aiken LB, Houmard JA, et al. Inactivity, exercise, and visceral fat. STRRIDE: a randomized, controlled study of exercise intensity and amount. J Appl Physiol. 2005;99(4):1613–1618.
- Yu XX, Watts LM, Manchem VP, et al. Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice. PLoS One. 2013;8(7):e66923.
- Pipeline. Ionis Pharmaceuticals, 2016; [cited 2016 Aug 3]. Available from: http://www.ionispharma.com/pipeline/
- Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond). 2008;32(Suppl 4):S7–12.
- Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612–622.
- LIPO-202. Neothetics Inc., 2016; [cited 2016 Aug 3]. Available from: http://neothetics.com/lipo.html
- Svane MS, Jørgensen NB, Bojsen-Møller KN, et al. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. Int J Obes (Lond). 2016: cited 30 August 2016. DOI:10.1038/ijo.2016.121
- Vilsbøll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
- Blundell J, Finlayson G, Axelsen M, et al. Semaglutide reduces appetite and energy intake, improves control of eating, and provides weight loss in subjects with obesity. Diabetes. 2016;65(supl1):abstract 23–OR.cited 2016 Aug 4. Available from: http://www.abstractsonline.com/pp8/#!/4008/presentation/43943
- Baron MA, Denham D, Prabhakar P, et al. Efficacy and tolerability of ITCA 650 versus sitagliptin in uncontrolled type 2 diabetes patients on metformin monotherapy: results of the FREEDOM-2 study. EASD Annu Meet 2016;Abstract 150.[cited 2016 Sep 19]. Available from: http://www.easdvirtualmeeting.org/resources/efficacy-and-tolerability-of-itca-650-versus-sitagliptin-in-uncontrolled-type-2-diabetes-patients-on-metformin-monotherapy-results-of-the-freedom-2-study
- Smith SR, Aronne LJ, Burns CM, et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31(9):1816–1823.
- Campbell JE, Drucker DJ. Islet α cells and glucagon–critical regulators of energy homeostasis. Nat Rev Endocrinol. 2015;11(6):329–338.
- Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27–36.
- Vorobiev I, Matskevich V, Kovnir S, et al. Chemical polysialylation: design of conjugated human oxyntomodulin with a prolonged anorexic effect in vivo. Biochimie. 2013;95(2):264–270.
- Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring). 2009;17(9):1736–1743.
- Amylin and Takeda voluntarily suspend clinical activities in obesity trial. Takeda Pharmaceutical Company Limited, 2011; [cited 2016 Aug 3]. Available from: https://www.takeda.com/news/2011/20110317_3836.html
- Amylin and Takeda discontinue development of pramlintide/metreleptin combination treatment for obesity following commercial reassessment of the program. Takeda Pharmaceutical Company Limited, 2011; [cited 2016 Aug 3]. Available from: http://www.takeda.com/news/2011/20110805_3889.html
- Müller TD, Sullivan LM, Habegger K, et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci. 2012;18(6):383–393.
- Clemmensen C, Chabenne J, Finan B, et al. GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. Diabetes. 2014;63(4):1422–1427.
- Wewer Albrechtsen NJ, Hornburg D, Albrechtsen R, et al. Oxyntomodulin identified as a marker of type 2 diabetes and gastric bypass surgery by mass-spectrometry based profiling of human plasma. EBioMedicine. 2016;7:112–120.
- Jacobsen SH, Olesen SC, Dirksen C, et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg. 2012;22(7):1084–1096.
- Nishizawa M, Nakabayashi H, Uehara K, et al. Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways. Am J Physiol Endocrinol Metab. 2013;305(3):E376–87.